Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluzoparib + apatinib + paclitaxel
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination consists of **fluzoparib** (a small molecule poly (ADP-ribose) polymerase [PARP] inhibitor), **apatinib** (a small molecule vascular endothelial growth factor receptor 2 [VEGFR2] inhibitor/anti-angiogenic agent), and **paclitaxel** (a taxane-based small molecule chemotherapeutic that stabilizes microtubules to inhibit mitosis). The combination is being explored for synergistic anti-tumor effects, particularly in recurrent ovarian cancer and triple-negative breast cancer, based on mechanisms that include DNA damage, inhibition of homologous recombination repair, anti-angiogenesis, and disruption of cell division. Preclinical and early clinical studies suggest enhanced antitumor efficacy compared to monotherapy regimens[1][3][5].
- Brand names
- AiRuiYiAiTanTaxol
- Other names
- SHR-1209SHR1209SHR 1209rivoceranibYN-968D1YN968D1YN 968D1
02
Targets
TUBB (Tubulin (alpha and beta subunits))VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on fluzoparib + apatinib + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluzoparib + apatinib + paclitaxel.